Amneal Pharmaceuticals, Valuation
| AMRX Stock | USD 8.35 0.10 1.21% |
At this time, the firm appears to be overvalued. Amneal Pharmaceuticals, shows a prevailing Real Value of $7.07 per share. The current price of the firm is $8.35. Our model approximates the value of Amneal Pharmaceuticals, from analyzing the firm fundamentals such as Current Valuation of 5.17 B, return on equity of -1.86, and Profit Margin of (0.07) % as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Amneal Pharmaceuticals,'s price fluctuation is somewhat reliable at this time. Calculation of the real value of Amneal Pharmaceuticals, is based on 3 months time horizon. Increasing Amneal Pharmaceuticals,'s time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Amneal Pharmaceuticals, is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Amneal Stock. However, Amneal Pharmaceuticals,'s intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 8.35 | Real 7.07 | Hype 8.38 | Naive 8.01 |
The intrinsic value of Amneal Pharmaceuticals,'s stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Amneal Pharmaceuticals,'s stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Amneal Pharmaceuticals, Class helps investors to forecast how Amneal stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Amneal Pharmaceuticals, more accurately as focusing exclusively on Amneal Pharmaceuticals,'s fundamentals will not take into account other important factors: Amneal Pharmaceuticals, Total Value Analysis
Amneal Pharmaceuticals, Class is presently projected to have valuation of 5.17 B with market capitalization of 3.81 B, debt of 2.75 B, and cash on hands of 87.33 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Amneal Pharmaceuticals, fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
5.17 B | 3.81 B | 2.75 B | 87.33 M |
Amneal Pharmaceuticals, Investor Information
About 53.0% of the company shares are held by company insiders. The company has Price/Earnings (P/E) ratio of 230.5. Amneal Pharmaceuticals, recorded a loss per share of 0.86. The entity had not issued any dividends in recent years. Based on the key measurements obtained from Amneal Pharmaceuticals,'s financial statements, Amneal Pharmaceuticals, Class is not in a good financial situation at this time. It has a very high probability of going through financial hardship in December.Amneal Pharmaceuticals, Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Amneal Pharmaceuticals, has an asset utilization ratio of 68.93 percent. This suggests that the Company is making $0.69 for each dollar of assets. An increasing asset utilization means that Amneal Pharmaceuticals, Class is more efficient with each dollar of assets it utilizes for everyday operations.Amneal Pharmaceuticals, Ownership Allocation
Amneal Pharmaceuticals, holds a total of 309.84 Million outstanding shares. Amneal Pharmaceuticals, Class retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Amneal Pharmaceuticals, Profitability Analysis
The company reported the previous year's revenue of 2.39 B. Net Loss for the year was (48.72 M) with profit before overhead, payroll, taxes, and interest of 791.46 M.About Amneal Pharmaceuticals, Valuation
Our relative valuation model uses a comparative analysis of Amneal Pharmaceuticals,. We calculate exposure to Amneal Pharmaceuticals,'s market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Amneal Pharmaceuticals,'s related companies.Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey. Amneal Pharmaceuticals operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on New York Stock Exchange. It employs 7000 people.
Amneal Pharmaceuticals, Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 176.1 M | |
| Quarterly Earnings Growth Y O Y | -0.75 | |
| Forward Price Earnings | 6.2972 |
Additional Tools for Amneal Stock Analysis
When running Amneal Pharmaceuticals,'s price analysis, check to measure Amneal Pharmaceuticals,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amneal Pharmaceuticals, is operating at the current time. Most of Amneal Pharmaceuticals,'s value examination focuses on studying past and present price action to predict the probability of Amneal Pharmaceuticals,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amneal Pharmaceuticals,'s price. Additionally, you may evaluate how the addition of Amneal Pharmaceuticals, to your portfolios can decrease your overall portfolio volatility.